Considering the importance of EFEMP1, we hypothesized that gradual expansion of methylation across its promoter during the development of IPMN serves as a biomarker for distinguishing malignant IPMNs from the non-malignant ones. This evidence concerns the gene EFEMP1 and pancreatic intraductal papillary-mucinous neoplasm.